Latest Daunorubicin Stories
PRINCETON, N.J., May 13 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the 2009 BIO International Convention in Atlanta. Mr.
PRINCETON, N.J., April 22 /PRNewswire/ -- Celator Pharmaceuticals today announced that new data from animal studies of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in consolidation treatment for leukemia and of CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection in combination with biological agents for the treatment of colorectal cancer were presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR) in Denver, Colorado (Abstracts 4568 and 4578)....
PRINCETON, N.J., March 26 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, has accepted an invitation to present at the Future Leaders in the Biotech Industry conference in New York. Mr.
The study is supported by The Leukemia & Lymphoma Society(R) PRINCETON, N.J., March 10 /PRNewswire/ -- Celator Pharmaceuticals today announced that the first patient has been treated in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus intensive salvage therapy in adult patients (up to 60 years old) with acute myeloid leukemia in first relapse.
Researchers at the Johns Hopkins University School of Medicine have discovered how a whole class of commonly used chemotherapy drugs can block cancer growth.
WHITE PLAINS, N.Y. and PRINCETON, N.J., Jan. 22 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Celator Pharmaceuticals, Inc.
PRINCETON, N.J., Jan. 8 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Biotech Showcase 2009 in San Francisco. Mr.
Findings confirm advantages of fixed-ratio drug delivery and lay the groundwork for Phase 2 trials already underway in first-line and first-relapse Acute Myeloid Leukemia (AML) settings PRINCETON, N.J., Dec.
Vion Pharmaceuticals, which develops and commercializes cancer therapeutics, has signed an agreement with the Institut Paoli-Calmettes in Marseille, France to conduct a multi-center Phase I/II clinical trial of laromustine with remission-induction therapy in patients aged 18-60 with previously untreated acute myelogenous leukemia and a poor prognosis based on their cytogenetic profile.
Celator Pharmaceuticals has announced that the FDA has granted orphan drug designation to CPX-351 liposome injection for the treatment of acute myeloid leukemia. Celator is currently preparing to conduct two randomized Phase II studies with CPX-351.